Rats treated with desoxycorticosterone acetate and sodium chloride (DOCA/ NaCl) developed a time-dependent increase in blood pressure which was associated with a reduced in vitro β- and an elevated α-adrenergic responsiveness. Isoproterenol-induced relaxation of aortic smooth muscle from the DOCA-NaCl-treated rats was similar to controls 1 week after treatment, was significantly attenuated as the blood pressure began to rise (week 4) and was completely abolished when the blood pressure exceeded 150 mm Hg (week 12). The aortic smooth muscle sensitivity to norepinephrine was significantly increased prior to (week 1), during the rise (week 4) and during the maintenance of an elevated systolic blood pressure (>150 mm Hg; week 12). No significant differences were observed between the two groups in either the contractile response of the aortic ring preparations to potassium chloride or in the relaxation properties in response to sodium nitrite. These results demonstrate that alterations in both the α- and β-adrenergic responsiveness occur in the DOCA/NaCl-treated animal. The enhancement of the α-adrenergic responsiveness occurs prior to any change in blood pressure, while the attenuated β-adrenergic responsiveness parallels the elevation in blood pressure, suggesting that these reciprocal alterations of adrenergic responsiveness may be responsible for the eventual development of hypertension induced with DOCA/NaCl treatment in rats.

Keywords:
DOCA/NaCl treatment, Blood pressure, Isoproterenol, Norepinephrine, Vascular reactivity, β- and α-adrenergic responsiveness
This content is only available via PDF.
© 1984 S. Karger AG, Basel
1984
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.